file copy

L10 ANSWER 23 OF 72 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1996:338506 CAPLUS
DOCUMENT NUMBER: 125:114539
TITLE: Cyclocondensation of activated (ortho-chloroaryl)acetylenes with hydrazine: a novel route to substituted indazoles
AUTHOR(S): Vasilevsky, Sergey F.; Prikhod'ko, Tat'yana A.
CORPORATE SOURCE: Inst. Chem. Kinetics and Combustion, Siberian Branch Russian Acad. Sci., Novosibirsk, 630090, Russia
SOURCE: Mendeleev Commun. (1996), (3), 98-99
CODEN: MENCEX; ISSN: 0959-9436
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II

AB The reaction of (ortho-chloroaryl)acetylenes I (R = 4-O2NC6H4, 6-methyl-3-pyridyl, 4-chloro-2,5-dimethyl-3-pyrazolyl), activated by electron-withdrawing substituents, with N2H4.cntdot.H2O afforded substituted indazoles II.

IT **178971-64-7P 178971-65-8P 178971-66-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(cyclocondensation of (chlorophenyl)acetylenes with hydrazine to give indazoles)

RN 178971-64-7 CAPLUS
CN 1H-Indazole, 5-nitro-3-[(4-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 178971-65-8 CAPLUS
CN 1H-Indazole, 3-[(6-methyl-3-pyridinyl)methyl]-5-nitro- (9CI) (CA INDEX NAME)



RN 178971-66-9 CAPLUS
CN 1H-Indazole, 3-[(4-chloro-1,3-dimethyl-1H-pyrazol-5-yl)methyl]-5-nitro- (9CI) (CA INDEX NAME)



L10 ANSWER 25 OF 72 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1995:490642 CAPLUS
DOCUMENT NUMBER: [redacted]
TITLE: Synthesis of 1-[4-(4-phenyl-1-piperazinyl)butyl]-1,2-dihydro-3H-1,4-benzodiazepin-2-ones and -1H-indazoles and their affinity for benzodiazepine receptors
AUTHOR(S): [redacted] S. A.; Kolodeyev, G. Ye.; Makan, S. Yu.; Sava, V. M.; Yavorsky, A. S.
CORPORATE SOURCE: Fiz.-Khim. Inst. im. A.V. Bogatskogo, Odessa, Ukraine
SOURCE: Dopov. Akad. Nauk Ukr. (1994), (8), 126-31
CODEN: DNUKEM
DOCUMENT TYPE: Journal
LANGUAGE: Russian
GI



I



II



III

AB Title compds. I (R = H, Cl) and II (R1 = Cl, Br, Me, R2 = H; R1 = Br, R2 = Cl) were prepd. by reaction of spiro compd. III with 1-unsubstituted benzodiazepinones and indazoles. The effect of the (phenylpiperazinyl)butyl group on the affinity to benzodiazepine receptors was examd.

IT **13097-03-5P 57614-16-1P 57639-16-4P 163434-09-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(effect of (phenylpiperazinyl)butyl group on benzodiazepine receptor affinity of benzodiazepinones and indazoles)

RN 13097-03-5 CAPLUS
CN 1H-Indazole, 5-chloro-3-phenyl- (8CI, 9CI) (CA INDEX NAME)



RN 57614-16-1 CAPLUS
CN 1H-Indazole, 5-methyl-3-phenyl- (9CI) (CA INDEX NAME)



RN 57639-16-4 CAPLUS
CN 1H-Indazole, 5-bromo-3-phenyl- (9CI) (CA INDEX NAME)



RN 163434-09-1 CAPLUS
CN 1H-Indazole, 5-bromo-3-(2-chlorophenyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 28 OF 72 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1994:299030 CAPLUS
DOCUMENT NUMBER: 120:299030
TITLE: Total synthesis of peruvianine, a phenolic 7-oxoaporphine alkaloid of Telitoxicum peruvianum
AUTHOR(S): Buck, Keith T.; Edgren, Denise L.; Blake, Geoffrey W.; Menachery, Mary D.
CORPORATE SOURCE: Fries Fries Div., Mallinckrodt, Inc., Cincinnati, OH, 45216, USA
SOURCE: Heterocycles (1993), 36(11), 2489-95
CODEN: HTCYAM; ISSN: 0385-5414
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 120:299030
GI



I



II

AB Peruvianine (I), a phenolic 7-oxoaporphine alkaloid from Telitoxicum peruvianum, has been synthesized via photo-Pschorr cyclization of an aminophenol precursor II.

IT **154458-84-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 154458-84-1 CAPLUS
CN 1H-Indazol-5-ol, 3-(6,7-dimethoxy-1-isoquinolinyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 32 OF 72 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1992:235509 CAPLUS
DOCUMENT NUMBER: 116:235509
TITLE: Azoles. Part 33. 5-Fluoroindazole derivatives
AUTHOR(S): Wrzeciono, U.; Majewska, K.; Buege, A.; Koehler, T.; Rickinger, O.; Nuhn, P.
CORPORATE SOURCE: Karol Marcinkowski Med. Akad., Poznan, 60-780, Pol.
SOURCE: Pharmazie (1992), 47(1), 22-4
CODEN: PHARAT; ISSN: 0031-7144
DOCUMENT TYPE: Journal
LANGUAGE: German

AB Nitration of 5-fluoroindazole gave the 1-, 2-, and 3-nitro derivs. which were converted to amines. 5-Fluoro-3-nitroindazole caused 32.9% inhibition of phospholipase A2 at 5 .times. 10-4 mol/L. and 5-chloro-3-nitroindazole gave 52.6% inhibition at the same concn. The fluoroindazoles and related chloroindazoles were inactive against 15-lipoxygenase.

IT **124673-62-7 124673-63-8**
RL: RCT (Reactant)
(lipoxygenase-inhibiting activity of)

RN 124673-62-7 CAPLUS
CN 1H-Indazole, 5-chloro-3-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 124673-63-8 CAPLUS
CN 1H-Indazole, 5-chloro-3-(4-methyl-1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT **141071-17-2P 141071-18-3P 141071-20-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 141071-17-2 CAPLUS
CN 1,3'-Bi-1H-indazole, 5,5'-difluoro-3-nitro- (9CI) (CA INDEX NAME)



RN 141071-18-3 CAPLUS
CN 1H-Indazole, 5-fluoro-3-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 141071-20-7 CAPLUS
CN 1H-Indazole, 5-fluoro-3-(1-piperidinyl)- (9CI) (CA INDEX NAME)



IT **141071-14-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn., acetylation, and antiinflammatory activity of)
RN 141071-14-9 CAPLUS
CN 1H-Indazole, 5-fluoro-3-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 37 OF 72 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1990:216936 CAPLUS
DOCUMENT NUMBER: 112:216936
TITLE: Preparation of pyrazolo[1,2-a]indazolium compounds as antiasthmatics
INVENTOR(S): Grayshan, Roger; French, Andrew McKinnon; Al-Khammees, Hamad; De Boos, Gareth Andrew
PATENT ASSIGNEE(S): National Research Development Corp., UK
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 8910924	A1	19891116	WO 1989-GB517	19890512
W: JP, US				
RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
JP 03504242	T2	19910919	JP 1989-505608	19890512

PRIORITY APPLN. INFO.: GB 1988-11299 19880512
WO 1989-GB517 19890512
OTHER SOURCE(S): MARPAT 112:216936
GI



I

AB Title compds. I [R1 = (un)substituted 6-membered N-heterocyclyl bound to a C to the indazole ring; R2 = H, HO, C1-6 alkyl, C1-6 alkoxy; R3, R4 = H, HO, halo, C1-6 alkyl, -alkoxy, O2N, cyano, H2NCO, RNHCO; R = C1-3 alkyl; R5 = H, halo; X = pharmaceutically acceptable anion; n = 1,2] useful as antiasthmatics (no data), are prepd. 3-(1-Methyl-1,2,5,6-tetrahydro-4-pyridyl)indazole (prepn. given) in DMF was added to NaH in DMF, and the mixt. added to Br(CH2)3Br in DMF to give 2,3-dihydro-9-(1,2,5,6 tetrahydro-1-methyl-4-pyridyl)pyrazole[1,2-a]indazolium bromide which was taken up in BuOH and aq. HCl to give the bromide-HCl.

IT **126971-86-6**
RL: RCT (Reactant)
(reaction of, in prepn. of antiasthmatic pyrazoloindazolium compds.)

RN 126971-86-6 CAPLUS
CN 1H-Indazole, 5-chloro-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)


H
N
N
Cl
N

L10 ANSWER 42 OF 72 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1987:598159 CAPLUS
DOCUMENT NUMBER: 107:198159
TITLE: Synthesis and pharmacological activities of 2,3-dihydro-1H-pyrazolo[1,2-a]indazolium derivatives
AUTHOR(S): Fujimura, Yasuo; Shiraki, Yasuyuki; Nawata, Yoshiharu; Matsunaga, Isao
CORPORATE SOURCE: Cent. Res. Lab., Chugai Pharm. Co., Ltd., Tokyo, 171, Japan
SOURCE: Yakugaku Zasshi (1986), 106(11), 1002-7
CODEN: YKKZAJ; ISSN: 0031-6903
DOCUMENT TYPE: Journal
LANGUAGE: Japanese
OTHER SOURCE(S): CASREACT 107:198159
GI



I



II

AB Pyrazoloindazolium halides I (R = H, 6-Me, 7-Me, 8-Me, 7-OMe, 7-OH, 7-OCH2Ph, 7-Br, 7-Cl, 7-CHO, 7-cyano, 7-CH2OH, 7-CO2H, 7-CO2Et; R1 = H, Br, Me, Et, Pr, Ph; X = Cl, Br) were prepd. by N-alkylation and cyclization of indazoles II with X(CH2)3Cl. I (R = 7-Me, R1 = Ph, X = Br) was more effective as a bronchodilator than isoproterenol and noradrenaline.

IT **65642-56-0P 83684-54-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn., alkylation, and cyclization of)

RN 65642-56-0 CAPLUS
CN 1H-Indazole-5-carboxaldehyde, 3-phenyl- (9CI) (CA INDEX NAME)



RN 83684-54-2 CAPLUS
CN 1H-Indazole-5-carbonitrile, 3-phenyl- (9CI) (CA INDEX NAME)





IT **57614-16-1**, 5-Methyl-3-phenylindazole
RL: RCT (Reactant)
(N-acetylation of)
RN 57614-16-1 CAPLUS
CN 1H-Indazole, 5-methyl-3-phenyl- (9CI) (CA INDEX NAME)



IT **13097-03-5**, 5-Chloro-3-phenylindazole
RL: RCT (Reactant)
(N-alkylation and cyclization of)
RN 13097-03-5 CAPLUS
CN 1H-Indazole, 5-chloro-3-phenyl- (8CI, 9CI) (CA INDEX NAME)



L10 ANSWER 46 OF 72 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1985:523405 CAPLUS
DOCUMENT NUMBER: 103:123405
TITLE: Azoles. Part 14: behavior of 5-chloro-2-nitroindazole against aliphatic and cyclic amines
AUTHOR(S): [redacted] U.; Dudzinska-Usarewicz, J.; Majewska, K.; Stasieczko-Rydelkiewicz, I.; Stefanowicz, J.; Nieweglowska, W.
CORPORATE SOURCE: Acad. Med., Poznan, PL-60-780, Pol.
SOURCE: Pharmazie (1985), 40(2), 105-8
CODEN: PHARAT; ISSN: 0031-7144
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 103:123405
GI



II



IV



VII

AB Acetylation of 5-chloroindazole (I) by Ac2O in pyridine gave 2-acetyl-5-chloroindazole (II, R = Ac) which, on nitration in Ac2O, gave 5-chloro-1-nitroindazole. Nitration of I gave a mixt. of II (R = NO2) (III) and 5-chloro-3-nitroindazole (IV, R1 = NO2) (V). Reaction of this mixt. with R2R3NH [R2 = Me, R3 = H; R2 = R3 = Me, Et; R2R3 = (CH2)4, (CH2)5, O(CH2CH2)2] gave a mixt. of IV (R1 = R2R3N) (VI), bimol. indazole VII, and unchanged V. V was also detected in the reaction of III alone with the amines, as III isomerized to V under the reaction conditions. This isomerization also occurred photochem. and thermally.

IT **98083-58-0P 98083-61-5P 98083-64-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and acetylation of)

RN 98083-58-0 CAPLUS
CN 1H-Indazole, 5-chloro-3-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 98083-61-5 CAPLUS
CN 1H-Indazole, 5-chloro-3-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 98083-64-8 CAPLUS
CN 1H-Indazole, 5-chloro-3-(4-morpholinyl)- (9CI) (CA INDEX NAME)



IT **98083-49-9P 98083-60-4P 98083-63-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 98083-49-9 CAPLUS
CN 1,3'-Bi-1H-indazole, 5,5'-dichloro-3-nitro- (9CI) (CA INDEX NAME)



RN 98083-60-4 CAPLUS
CN 1H-Indazole, 5-chloro-3-(1-pyrrolidinyl)-, monohydrochloride (9CI) (CA

INDEX NAME)



● HCl

RN 98083-63-7 CAPLUS
CN 1H-Indazole, 5-chloro-3-(1-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L10 ANSWER 49 OF 72 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1984:51503 CAPLUS
DOCUMENT NUMBER: 100:51503
TITLE: The reaction of 4-alkyl-3-thiosemicarbazides with .beta.-halo ketones
AUTHOR(S): Jones, Winton D., Jr.; Kane, John M.; Sill, Arthur D.
CORPORATE SOURCE: Merrell Res. Cent., Merrell Dow Pharm. Inc., Cincinnati, OH, 45215, USA
SOURCE: J. Heterocycl. Chem. (1983), 20(5), 1359-61
CODEN: JHTCAD; ISSN: 0022-152X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 100:51503

AB The reactions of 4-alkyl-3-thiosemicarbazides with .beta.-haloalkanophenones and o-halobenzophenones gave 4,5-dihydro-N-alkyl-3-phenyl-1H-pyrazole-1-carbothioamides and 3-phenyl-1H-indazoles, resp.

IT **57614-63-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 57614-63-8 CAPLUS
CN 1H-Indazole, 5-fluoro-3-phenyl- (9CI) (CA INDEX NAME)



L10 ANSWER 51 OF 72 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1982:472295 CAPLUS
DOCUMENT NUMBER: 97:72295
TITLE: Preparation of 1H-indazoles by photolysis of 2-aminophenyl ketone O-(ethoxycarbonyl)oximes and of 3,1,4-benzoxadiazepine-2(1H)-ones
AUTHOR(S): Pfoertner, Kral Heinz; Foricher, Joseph
CORPORATE SOURCE: Zent. Forschungseinheiten, F. Hoffmann-La Roche und Co. A.-G., Basel, CH-4002, Switz.
SOURCE: Helv. Chim. Acta (1982), 65(3), 798-806
CODEN: HCACAV; ISSN: 0018-019X
DOCUMENT TYPE: Journal
LANGUAGE: German
GI



I

AB Indazoles I (R = Ph, 2-pyridyl; R1 = H, Me; R2 = Cl, Br) were obtained by photolysis of (E)- and (Z)- 2,5-R3R2C6H3CR:NOCO2Et (II, R3 = NHR1). II (R3 = NMe2) did not cyclize to I. II did not undergo E-Z isomerization. The mechanism of the photolysis reaction is discussed.

IT **13097-03-5P 82616-92-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 13097-03-5 CAPLUS
CN 1H-Indazole, 5-chloro-3-phenyl- (8CI, 9CI) (CA INDEX NAME)



RN 82616-92-0 CAPLUS
CN 1H-Indazole, 5-bromo-3-(2-pyridinyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 59 OF 72 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1978:37692 CAPLUS
DOCUMENT NUMBER: 88:37692
TITLE: Synthesis of nitroheterocycles: Part IV. Syntheses of 1-substituted 4-nitroisoquinolines, 5- and 6-nitroindazoles and 6-nitrobenzimidazoles
AUTHOR(S): Arya, V. P.; Fernandes, F.; Honkan, V.; Ray, D. K.; Shrivastava, V. B.
CORPORATE SOURCE: Ciba-Geigy Res. Cent., Bombay, India
SOURCE: Indian J. Chem., Sect. B (1977), 15B(7), 625-8
CODEN: IJSBDB
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



III, R=$NHCH_2CH(OMe)_2$



IV



V



VI

AB 1-Chloro-4-nitroisoquinoline (I) was treated with oxazolidin-2-one and thiazolidin-2-one in the presence of NaH to give II (X = O, S), resp. Reaction of I with H2NCH2CH(OMe)2 gives III which was cyclized to give IV. 5- And 6-nitroindazoles react with 2-halo-3- or 5-substituted-pyridines in the presence of NaH in DMF to yield 1-substituted 5- and 6-nitroindazoles (e.g., V). Similar reaction of 6-nitrobenzimidazole sodium salt with compds. contg. reactive chlorine affords 1-substituted-6-nitrobenzimidazoles (e.g., VI). The prepd. compds. possess no appreciable in vivo antibacterial, antifungal, antiamoebic or antiparasitic activity.

IT **65092-57-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 65092-57-1 CAPLUS
CN 1H-Indazole, 3-(1H-imidazol-1-yl)-5-nitro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L10 ANSWER 65 OF 72 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1976:31053 CAPLUS
DOCUMENT NUMBER: 84:31053
TITLE: Indazole derivatives
INVENTOR(S): Fujimura, Yasuo; Nagano, Hiroyuki; Shindo, Minoru; Kakimoto, Morio; Iwasaki, Tsuneo; Ikeda, Yugo
PATENT ASSIGNEE(S): Chugai Pharmaceutical Co., Ltd., Japan
SOURCE: Ger. Offen., 27 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2503815	A1	19750807	DE 1975-2503815	19750130
DE 2503815	C2	19860522		
JP 50106958	A2	19750822	JP 1974-12184	19740131
JP 56037984	B4	19810903		
JP 50148355	A2	19751127	JP 1974-55000	19740518
JP 59022708	B4	19840528		
JP 50154244	A2	19751212	JP 1974-61853	19740603
JP 56052904	B4	19811215		
JP 51056446	A2	19760518	JP 1974-129521	19741112
JP 60003063	B4	19850125		
JP 51063172	A2	19760601	JP 1974-135184	19741126
JP 59044313	B4	19841029		
GB 1489280	A	19771019	GB 1975-2247	19750117
FR 2259601	A1	19750829	FR 1975-2955	19750130
FR 2259601	B1	19800111		

PRIORITY APPLN. INFO.:
JP 1974-12184 19740131
JP 1974-55000 19740518
JP 1974-61853 19740603
JP 1974-129521 19741112
JP 1974-135184 19741126

GI For diagram(s), see printed CA Issue.

AB Indazoles I (R = R1 = H, Me, Et; R = H, R1 = Me, Bu, allyl; NRR1 = piperidino, morpholino, N-methylpiperazino, N-phenylpiperazino, 2-(4-chlorophenyl-4-methyl-1,2,3,6-tetrahydropyridino, pyrrolidino; R2 = H, Cl, Me, Br, F; n = 1-3) were prepd. by treating indazoles with Cl(CH2)nNRR1, by Mannich reaction of indazoles, or by redn. of carbamoylalkylindazoles. Thus, 3-phenylindazole was treated with Me2NCH2CH2Cl.HCl to give I (R = R1 = Me, R2 = H, n = 2), which at 100 mg/kg orally in mice had a barbiturate potentiation value of 3.0, compared with imipramine 1.3. I were also antidepressant.

IT **57614-63-8**
RL: RCT (Reactant)
(Mannich reaction of, with piperidine)

RN 57614-63-8 CAPLUS
CN 1H-Indazole, 5-fluoro-3-phenyl- (9CI) (CA INDEX NAME)





IT **13097-03-5 57614-16-1 57639-16-4**
RL: RCT (Reactant)
(aminoalkylation of)
RN 13097-03-5 CAPLUS
CN 1H-Indazole, 5-chloro-3-phenyl- (8CI, 9CI) (CA INDEX NAME)



RN 57614-16-1 CAPLUS
CN 1H-Indazole, 5-methyl-3-phenyl- (9CI) (CA INDEX NAME)



RN 57639-16-4 CAPLUS
CN 1H-Indazole, 5-bromo-3-phenyl- (9CI) (CA INDEX NAME)



L10 ANSWER 66 OF 72 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1975:564108 CAPLUS
DOCUMENT NUMBER: 83:164108
TITLE: Nucleophilic displacement of aromatic fluorine. I. Synthesis of benzisoxazoles
AUTHOR(S): Walser, Armin; Flynn, Thomas; Fryer, R. Ian
CORPORATE SOURCE: Chem. Res. Dep., Hoffmann-La Roche Inc., Nutley, N. J., USA
SOURCE: J. Heterocycl. Chem. (1974), 11(6), 885-8
CODEN: JHTCAD
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB The quinazoline 3-oxides I (R = H, Cl) convert to the benzisoxazoloquinazolines II by heating in Ac2O. The dihydroquinazoline-3-oxides III underwent aromatization under the same conditions. Hydrolysis of I or II gave the 3-(2-aminophenyl)benzisoxazoles IV which could be rearranged to the 3-(2-hydroxyphenyl)indazoles V with hydride. Possible mechanisms are discussed.
IT **55076-04-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 55076-04-5 CAPLUS
CN Phenol, 2-(5-chloro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



L10 ANSWER 70 OF 72 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1969:77962 CAPLUS
DOCUMENT NUMBER: 70:77962
TITLE: 3-Substituted indoles and indazoles
INVENTOR(S): Horner, Leopold; Sues, Oskar; Simon, Ulrich
PATENT ASSIGNEE(S): Kalle A.-G.
SOURCE: Ger., 5 pp.
CODEN: GWXXAW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1266763		19680425	DE	19650727

GI For diagram(s), see printed CA Issue.

AB The title compds. (I and II) are synthetic intermediates and are prepd. by photolytic reactions of 3-diazoindoles and 3-diazoindazoles with R1H solvents. 3-Diazo-2-phenylindole (2.2 g.) in 330 ml. cyclopentene irradiated with a high-pressure Hg lamp until N evolution stops (3.5 hrs.), and the soln. worked up gave 1.15 g. 3-(2-cyclopentenyl)-2-phenylindole, m. 163-4.degree. (C6H6-cyclohexane). Similarly were obtained the following I (R1, R2, and m.p. given): 2-cyclohexenyl, Ph, 161-2.degree.; 2-cyclooctenyl, Ph, 138-40.degree.; cyclohexyl, Ph, 158-9.degree.; cyclohexyl, Me, - (picrate m. 180-1.degree.); Ph, Me, 59-60.degree.; 4-MeOC6H4, Ph, 124-5; and Ph, Ph, 189-90.degree.. 3-Diazo-6-chloroindazole (3.6 g.) in 750 ml. C6H6 exposed 6 hrs. to direct sunlight, and the product purified by chromatog. on neutral Al2O3 in Me2CO gave 3.3 g. 3-phenyl-6-chloroindazole, m. 151-3.degree. (C6H6-cyclohexane). Similarly were prepd. the following II (R1, R2, and m.p. given): Ph8 5-Cl, 135-6.degree.; 2-pyridyl, 6-Cl, 159-60.degree.; 2(or 3)-thienyl, 6-Cl, 186-7.degree.; Ph, H, 115-16.degree.; 2(or 3),5(or 6)-ClMeC6H3(Z), H, 141-2.degree.; Ph, 4-Cl, 204-5.degree.; Z, 6-Cl, 169-70; 2,3(or 3,4)-(MeO)2C6H3, 6-Cl, 166-7.degree.; NCC6H4, 6-Cl, 288-90.degree.; MeO2CC6H4, 6-Cl, 174-5.degree.; and Ph, 5-OMe, 133-4.degree..

IT **13097-03-5P 13097-05-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 13097-03-5 CAPLUS
CN 1H-Indazole, 5-chloro-3-phenyl- (8CI, 9CI) (CA INDEX NAME)



RN 13097-05-7 CAPLUS
CN 1H-Indazole, 5-methoxy-3-phenyl- (8CI) (CA INDEX NAME)


H
N
N
MeO
Ph

File Copy

L9 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:545668 CAPLUS
DOCUMENT NUMBER: 135:137505
TITLE: Synthesis of disubstituted indazole compounds as cyclin dependent kinase inhibitors and methods for inhibiting cell proliferation
INVENTOR(S): Reich, Siegfried Heinz; Bleckman, Ted Michael; Kephart, Susan Elizabeth; Romines, William Henry, III; Wallace, Michael B.
PATENT ASSIGNEE(S): Agouron Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 183 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001053268	A2	20010726	WO 2001-US1477	20010118
WO 2001053268	A3	20011227		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1250326	A2	20021023	EP 2001-942620	20010118
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2002161022	A1	20021031	US 2001-761656	20010118 <--
BR 2001007783	A	20021119	BR 2001-7783	20010118
NO 2002002117	A	20020916	NO 2002-2117	20020503

PRIORITY APPLN. INFO.: US 2000-176484P P 20000118
WO 2001-US1477 W 20010118

OTHER SOURCE(S): MARPAT 135:137505
GI



I

AB Title compds. I [R1 = alkyl, aryl, heteroaryl, carbocycle, heterocycle, etc.; R2 = alkyl, aryl, heteroaryl, carbocycle, heterocycle, etc.] were prepd. Examples include over 90 synthetic examples and 8 bioassays. For instance, 5-amino-1H-indazole was converted to 5-chloro-3-iodo-1H-indazole by diazotization/chlorination (NaNO2, HCl, 0.degree.C/CuCl, 60.degree.C) followed by iodination (I2, NaOHaq). Protection as the N-SEM deriv. and sequential Suzuki coupling with (E)-.beta.-styreneboronic acid to the 3 position and phenylboronic acid to the 5-position yielded N-SEM deriv. I (R1 = (E)-.beta.-styrenyl; R2 = Ph). Deprotection with 3M HCl in EtOH at

reflux afforded I (R1 = (E)-.beta.-styrenyl; R2 = Ph; II). II had Ki = 1.7 .mu.M for cdk4/cyclin D3 complex and Ki = 6.7 .mu.M for chk1 protein kinase. Selected examples of I were also assayed for cytotoxicity (HCT 116 cell line, 69 examples). The invention is also directed to methods of treating cancer and disease states assocd. with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis.

IT **351454-76-7P 351454-82-5P 351456-19-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(synthesis of disubstituted indazole compds. as cyclin dependent kinase inhibitors and methods for inhibiting cell proliferation)

RN 351454-76-7 CAPLUS
CN 1H-Indazole, 3-(1H-benzimidazol-2-yl)-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 351454-82-5 CAPLUS
CN 1H-Indazole, 3-(1H-benzimidazol-2-yl)-5-(3-methoxy-2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 351456-19-4 CAPLUS
CN 3-Pyridinemethanol, 5-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-4-methyl- (9CI) (CA INDEX NAME)



IT **351454-59-6P 351454-61-0P 351454-64-3P**
351454-67-6P 351454-70-1P 351454-73-4P

351454-79-0P 351454-85-8P 351454-88-1P
351454-91-6P 351454-94-9P 351454-97-2P
351455-00-0P 351455-03-3P 351455-06-6P
351455-09-9P 351455-12-4P 351455-15-7P
351455-18-0P 351455-21-5P 351455-23-7P
351455-26-0P 351455-28-2P 351455-30-6P
351455-32-8P 351455-34-0P 351455-36-2P
351455-38-4P 351455-40-8P 351455-42-0P
351455-44-2P 351455-45-3P 351455-46-4P
351455-47-5P 351455-49-7P 351455-51-1P
351455-53-3P 351455-55-5P 351455-57-7P
351455-59-9P 351455-61-3P 351455-63-5P
351455-65-7P 351455-67-9P 351455-69-1P
351455-71-5P 351455-73-7P 351455-75-9P
351455-77-1P 351455-79-3P 351455-81-7P
351455-83-9P 351455-85-1P 351455-87-3P
351455-89-5P 351455-91-9P 351455-93-1P
351455-95-3P 351455-97-5P 351455-99-7P
351456-01-4P 351456-03-6P 351456-05-8P
351456-07-0P 351456-09-2P 351456-11-6P
351456-13-8P 351456-15-0P 351456-17-2P
351456-21-8P 351456-23-0P 351456-25-2P
351456-27-4P 351456-28-5P 351456-29-6P
351456-30-9P 351456-31-0P 351456-32-1P
351456-33-2P 351456-34-3P 351456-35-4P
351456-36-5P 351456-37-6P 351456-38-7P
351456-39-8P 351456-40-1P 351456-41-2P
351456-42-3P 351456-43-4P 351456-44-5P
351458-50-9P 351458-51-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis of disubstituted indazole compds. as cyclin dependent kinase inhibitors and methods for inhibiting cell proliferation)

RN 351454-59-6 CAPLUS
CN 1H-Indazole, 5-phenyl-3-[(1E)-2-phenylethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 351454-61-0 CAPLUS
CN 1H-Indazole, 3,5-bis[(1E)-2-phenylethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 351454-64-3 CAPLUS
CN 1H-Indazole, 3-(1H-benzimidazol-2-yl)-5-phenyl- (9CI) (CA INDEX NAME)



RN 351454-67-6 CAPLUS
CN Phenol, 3-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)



RN 351454-70-1 CAPLUS
CN 1H-Indazole, 3-(1H-benzimidazol-2-yl)-5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 351454-73-4 CAPLUS
CN 1H-Indazole, 3-(1H-benzimidazol-2-yl)-5-(2-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 351454-79-0 CAPLUS
CN Phenol, 4-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)



RN 351454-85-8 CAPLUS
CN Phenol, 3-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 351454-88-1 CAPLUS
CN 1H-Indazole, 5-(2-methylphenyl)-3-phenyl- (9CI) (CA INDEX NAME)



RN 351454-91-6 CAPLUS
CN 1H-Indazole, 3-phenyl-5-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 351454-94-9 CAPLUS
CN Phenol, 3-methyl-4-(3-phenyl-1H-indazol-5-yl)- (9CI) (CA INDEX NAME)



RN 351454-97-2 CAPLUS
CN 1H-Indazole, 3-phenyl-5-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 351455-00-0 CAPLUS
CN Phenol, 2-methyl-3-[3-[(1E)-2-phenylethenyl]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 351455-03-3 CAPLUS
CN Isoquinoline, 4-[3-[(1E)-2-phenylethenyl]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 351455-06-6 CAPLUS
CN Quinoline, 4-[3-[(1E)-2-phenylethenyl]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 351455-09-9 CAPLUS
CN 1H-Indazole, 5-(4-pyridinyl)-3-(1H-pyrrol-2-yl)- (9CI) (CA INDEX NAME)



RN 351455-12-4 CAPLUS
CN Isoquinoline, 4-[3-(4-chloro-1H-benzimidazol-2-yl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)



RN 351455-15-7 CAPLUS
CN Isoquinoline, 4-[3-[5-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)



RN 351455-18-0 CAPLUS

CN 1H-Benzimidazol-4-ol, 2-[5-(3-hydroxy-2-methylphenyl)-1H-indazol-3-yl]- (9CI) (CA INDEX NAME)



RN 351455-21-5 CAPLUS
CN Benzenepropanol, 2-hydroxy-3-methyl-4-[3-[(1E)-2-phenylethenyl]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 351455-23-7 CAPLUS
CN 1H-Benzimidazole-4-methanol, 2-[5-(3-hydroxy-2-methylphenyl)-1H-indazol-3-yl]- (9CI) (CA INDEX NAME)



RN 351455-26-0 CAPLUS
CN Isoquinoline, 7-[3-[(1E)-2-phenylethenyl]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 351455-28-2 CAPLUS
CN Isoquinoline, 4-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)



RN 351455-30-6 CAPLUS
CN Benzenepropanol, 4-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-2-hydroxy-3-methyl- (9CI) (CA INDEX NAME)



RN 351455-32-8 CAPLUS
CN 4-Piperidinol, 1-[3-[(1E)-2-phenylethenyl]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 351455-34-0 CAPLUS
CN 3-Piperidinol, 1-[3-[(1E)-2-phenylethenyl]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 351455-36-2 CAPLUS
CN 1H-Benzimidazole-4-methanol, 2-[5-(4-isoquinolinyl)-1H-indazol-3-yl]- (9CI) (CA INDEX NAME)



RN 351455-38-4 CAPLUS
CN 1H-Benzimidazole-4-ethanol, 2-[5-(4-isoquinolinyl)-1H-indazol-3-yl]- (9CI) (CA INDEX NAME)



RN 351455-40-8 CAPLUS
CN 1H-Benzimidazole-4-methanamine, 2-[5-(4-isoquinolinyl)-1H-indazol-3-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 351455-42-0 CAPLUS
CN 1H-Benzimidazole-4-methanamine, 2-[5-(4-isoquinolinyl)-1H-indazol-3-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 351455-44-2 CAPLUS
CN Isoquinoline, 4-[3-[4-(1-pyrrolidinylmethyl)-1H-benzimidazol-2-yl]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)



RN 351455-45-3 CAPLUS
CN Isoquinoline, 4-[3-[4-[2-(1-pyrrolidinyl)ethyl]-1H-benzimidazol-2-yl]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)



RN 351455-46-4 CAPLUS
CN 1-Propanol, 3-[[[2-[5-(4-isoquinolinyl)-1H-indazol-3-yl]-1H-benzimidazol-4-yl]methyl]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 351455-47-5 CAPLUS
CN 1H-Benzimidazole-4-methanamine, N,N-diethyl-2-[5-(4-isoquinolinyl)-1H-indazol-3-yl]- (9CI) (CA INDEX NAME)



RN 351455-49-7 CAPLUS
CN 1H-Benzimidazole-4-methanamine, N-ethyl-2-[5-(4-isoquinolinyl)-1H-indazol-3-yl]- (9CI) (CA INDEX NAME)



RN 351455-51-1 CAPLUS
CN 1H-Benzimidazole-4-methanamine, 2-[5-(4-isoquinolinyl)-1H-indazol-3-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 351455-53-3 CAPLUS
CN 1H-Benzimidazole-4-methanamine, N-(1,1-dimethylethyl)-2-[5-(4-isoquinolinyl)-1H-indazol-3-yl]- (9CI) (CA INDEX NAME)



RN 351455-55-5 CAPLUS
CN Isoquinoline, 4-[3-[4-(1H-imidazol-1-ylmethyl)-1H-benzimidazol-2-yl]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)



RN 351455-57-7 CAPLUS
CN 1H-Indazole, 5-(3-methyl-4-pyridinyl)-3-[(1E)-2-phenylethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 351455-59-9 CAPLUS
CN 1H-Indazole, 5-(4-chloro-3-pyridinyl)-3-[(1E)-2-phenylethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 351455-61-3 CAPLUS
CN 1H-Indazole, 5-(4-methyl-3-pyridinyl)-3-[(1E)-2-phenylethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 351455-63-5 CAPLUS
CN Isoquinoline, 5-fluoro-4-[3-[(1E)-2-phenylethenyl]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 351455-65-7 CAPLUS
CN 8-Isoquinolinamine, 4-[3-[(1E)-2-phenylethenyl]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 351455-67-9 CAPLUS
CN 1H-Indazole, 5-(4-chloro-5-ethyl-3-pyridinyl)-3-[(1E)-2-phenylethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 351455-69-1 CAPLUS
CN Phenol, 3-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 351455-71-5 CAPLUS
CN 1H-Indazole, 3-(1H-benzimidazol-2-yl)-5-(1H-indol-4-yl)- (9CI) (CA INDEX NAME)



RN 351455-73-7 CAPLUS
CN Phenol, 3-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-2,4-difluoro- (9CI) (CA INDEX NAME)



RN 351455-75-9 CAPLUS
CN Phenol, 4-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-3,5-difluoro- (9CI) (CA INDEX NAME)



RN 351455-77-1 CAPLUS
CN Phenol, 2-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-3,5-difluoro- (9CI) (CA INDEX NAME)



RN 351455-79-3 CAPLUS
CN 1H-Indazole, 3-(1H-benzimidazol-2-yl)-5-(4-chloro-3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 351455-81-7 CAPLUS
CN 1H-Indazole, 3-(1H-benzimidazol-2-yl)-5-(4-methyl[3,4'-bipyridin]-5-yl)- (9CI) (CA INDEX NAME)





RN 351455-83-9 CAPLUS
CN 1,7-Naphthyridine, 5-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)



RN 351455-85-1 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-8-isoquinolinyl]- (9CI) (CA INDEX NAME)



RN 351455-87-3 CAPLUS
CN Acetamide, N-[4-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-8-isoquinolinyl]- (9CI) (CA INDEX NAME)



RN 351455-89-5 CAPLUS
CN 8-Isoquinolinamine, 4-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 351455-91-9 CAPLUS
CN 1H-Indazole, 3-(1H-benzimidazol-2-yl)-5-(4-methyl[3,3'-bipyridin]-5-yl)- (9CI) (CA INDEX NAME)



RN 351455-93-1 CAPLUS
CN 2-Propen-1-ol, 3-[5-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-4-methyl-3-pyridinyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 351455-95-3 CAPLUS
CN 3-Pyridinepropanol, 5-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-4-methyl- (9CI) (CA INDEX NAME)



RN 351455-97-5 CAPLUS
CN 1H-Indazole, 3-(1H-benzimidazol-2-yl)-5-(4-ethyl[3,4'-bipyridin]-5-yl)- (9CI) (CA INDEX NAME)



RN 351455-99-7 CAPLUS
CN 1H-Indazole, 3-(1H-benzimidazol-2-yl)-5-(4'-methyl[2,3'-bipyridin]-5'-yl)-
(9CI) (CA INDEX NAME)



RN 351456-01-4 CAPLUS
CN 1,7-Naphthyridine, 1-acetyl-5-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-
1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)



RN 351456-03-6 CAPLUS
CN 3-Pyridinecarboxamide, 5-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-4-methyl- (9CI) (CA INDEX NAME)



RN 351456-05-8 CAPLUS
CN 1H-Indazole, 3-(1H-benzimidazol-2-yl)-5-[5-(1H-imidazol-4-yl)-4-methyl-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 351456-07-0 CAPLUS
CN Isoquinoline, 4-[3-(4,5,6,7-tetrahydro-1H-benzimidazol-2-yl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)



RN 351456-09-2 CAPLUS
CN Isoquinoline, 4-[3-(4-methyl-5-phenyl-1H-imidazol-2-yl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)



RN 351456-11-6 CAPLUS
CN 1H-Benzimidazole-4-methanamine, N,N-dimethyl-2-[5-(4-methyl[3,4'-bipyridin]-5-yl)-1H-indazol-3-yl]- (9CI) (CA INDEX NAME)



RN 351456-13-8 CAPLUS
CN Benzenemethanol, 3-[5-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-4-methyl-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 351456-15-0 CAPLUS
CN Methanesulfonamide, N-[2-[5-(4-isoquinolinyl)-1H-indazol-3-yl]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)



RN 351456-17-2 CAPLUS
CN Methanesulfonamide, N-[2-[5-(4-methyl[3,4'-bipyridin]-5-yl)-1H-indazol-3-yl]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)



RN 351456-21-8 CAPLUS
CN 3-Pyridinemethanamine, 5-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-N,N,4-trimethyl- (9CI) (CA INDEX NAME)



RN 351456-23-0 CAPLUS
CN 3-Pyridinemethanamine, 5-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-N-ethyl-4-methyl- (9CI) (CA INDEX NAME)



RN 351456-25-2 CAPLUS
CN 1H-Indazole, 3-(1H-benzimidazol-2-yl)-5-(4,5-dimethyl-3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 351456-27-4 CAPLUS
CN Quinoline, 3-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-4-methyl- (9CI) (CA INDEX NAME)



RN 351456-28-5 CAPLUS
CN 3-Pyridinol, 5-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-4-methyl- (9CI) (CA INDEX NAME)



RN 351456-29-6 CAPLUS
CN 3-Pyridinemethanamine, 5-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-4-

methyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 351456-30-9 CAPLUS
CN 1H-Pyrrol-1-amine, N-[[5-(4-isoquinolinyl)-1H-indazol-3-yl]methylene]- (9CI) (CA INDEX NAME)



RN 351456-31-0 CAPLUS
CN 1H-Benzimidazole-4-carboxamide, 2-[5-[5-[(ethylamino)methyl]-4-methyl-3-pyridinyl]-1H-indazol-3-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 351456-32-1 CAPLUS
CN 3-Pyridinemethanamine, N-ethyl-4-methyl-5-[3-[4-(methylthio)-1H-benzimidazol-2-yl]-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)



RN 351456-33-2 CAPLUS
CN Acetamide, N-[2-[5-[5-[(ethylamino)methyl]-4-methyl-3-pyridinyl]-1H-indazol-3-yl]-1H-benzimidazol-4-yl]- (9CI) (CA INDEX NAME)



RN 351456-34-3 CAPLUS
CN 1H-Indazole, 5-(2,6-difluorophenyl)-3-phenyl- (9CI) (CA INDEX NAME)



RN 351456-35-4 CAPLUS
CN 1H-Indazol-5-amine, 3-(1H-pyrrol-2-yl)- (9CI) (CA INDEX NAME)



Claim 12

RN 351456-36-5 CAPLUS
CN 1H-Indazol-5-amine, N-(phenylmethyl)-3-(1H-pyrrol-2-yl)- (9CI) (CA INDEX NAME)



Claim 12

RN 351456-37-6 CAPLUS
CN 1H-Indazole, 5-(3-methoxyphenyl)-3-phenyl- (9CI) (CA INDEX NAME)



RN 351456-38-7 CAPLUS
CN 3-Pyridinemethanamine, 5-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-N-(1,1-dimethylethyl)-4-methyl- (9CI) (CA INDEX NAME)



RN 351456-39-8 CAPLUS
CN 3-Pyridinemethanamine, 5-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-4-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 351456-40-1 CAPLUS
CN Ethanol, 2-[[[5-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-4-methyl-3-pyridinyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 351456-41-2 CAPLUS
CN 1H-Benzimidazole-4-methanamine, 2-[5-(4-isoquinolinyl)-1H-indazol-3-yl]-N,.alpha.-dimethyl- (9CI) (CA INDEX NAME)



RN 351456-42-3 CAPLUS
CN 1H-Indazole, 3-(1H-benzimidazol-2-yl)-5-[4-methyl-5-(4-morpholinylmethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 351456-43-4 CAPLUS
CN 3-Pyridinemethanamine, 5-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-N-cyclopentyl-4-methyl- (9CI) (CA INDEX NAME)



RN 351456-44-5 CAPLUS
CN 3-Pyridinemethanamine, 5-[3-(1H-benzimidazol-2-yl)-1H-indazol-5-yl]-4-methyl-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 351458-50-9 CAPLUS
CN 1H-Indazole, 3-phenyl-5-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 351458-51-0 CAPLUS
CN 1H-Indazole, 5-nitro-3-(1H-pyrrol-2-yl)- (9CI) (CA INDEX NAME)



IT **293758-67-5P 351456-92-3P 351457-10-8P**
351457-27-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of disubstituted indazole compds. as cyclin dependent kinase inhibitors and methods for inhibiting cell proliferation)

RN 293758-67-5 CAPLUS
CN 1H-Indazole, 5-nitro-3-phenyl- (9CI) (CA INDEX NAME)



RN 351456-92-3 CAPLUS
CN 1H-Indazole, 5-(3-methoxy-2-methylphenyl)-3-[(1E)-2-phenylethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 351457-10-8 CAPLUS
CN 1H-Indazole, 5-(4-pyridinyl)-3-[1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-pyrrol-2-yl]- (9CI) (CA INDEX NAME)



RN 351457-27-7 CAPLUS
CN 1H-Benzimidazol-4-ol, 2-[5-(3-methoxy-2-methylphenyl)-1H-indazol-3-yl]-
(9CI) (CA INDEX NAME)